Citadel Advisors
OVID icon

Citadel Advisors’s Ovid Therapeutics OVID Stock Holding History

Citadel Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.5K Buy
20,500
+3,800
+23% +$6.79K ﹤0.01% 12436
2025
Q4 		$27.2K Sell
16,700
-45,800
-73% -$70.5K ﹤0.01% 12258
2025
Q3 		$81.3K Buy
+62,500
New +$54.2K ﹤0.01% 11965
2025
Q2 		– Sell
-100
Closed -$31 – 14374
2025
Q1 		$31 Sell
100
-100
-50% -$61 ﹤0.01% 14350
2024
Q4 		$187 Sell
200
-300
-60% -$336 ﹤0.01% 14370
2024
Q3 		$590 Buy
500
+300
+150% +$313 ﹤0.01% 13990
2024
Q2 		$154 Sell
200
-100
-33% -$278 ﹤0.01% 14085
2024
Q1 		$915 Buy
+300
New +$1K ﹤0.01% 14224
2023
Q3 		– Sell
-200
Closed -$656 – 14869
2023
Q2 		$656 Hold
200
– – ﹤0.01% 14069
2023
Q1 		$516 Buy
+200
New +$474 ﹤0.01% 14478
2021
Q4 		– Sell
-33,800
Closed -$114K – 14477
2021
Q3 		$114K Buy
33,800
+3,500
+12% +$12.8K ﹤0.01% 12705
2021
Q2 		$118K Sell
30,300
-95,300
-76% -$376K ﹤0.01% 12763
2021
Q1 		$505K Buy
125,600
+2,500
+2% +$8.3K ﹤0.01% 9660
2020
Q4 		$284K Buy
123,100
+80,600
+190% +$376K ﹤0.01% 9165
2020
Q3 		$244K Buy
42,500
+13,000
+44% +$87K ﹤0.01% 8484
2020
Q2 		$217K Buy
+29,500
New +$138K ﹤0.01% 8409

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Citadel Advisors's OVID Position: Q1 2026 in Review

Citadel Advisors reduced its Ovid Therapeutics (OVID) stake by 54% in Q1 2026, selling an estimated $769K and leaving 367,902 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #8136.

Citadel Advisors first reported a position in OVID in Q2 2017 and has held it in 21 quarters since. The position peaked at $1.3M in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Citadel Advisors held 367,902 shares of Ovid Therapeutics worth $817K as of Q1 2026.
  • Citadel Advisors sold 429,922 Ovid Therapeutics shares in Q1 2026, an estimated $769K.
  • Ovid Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8136 holding.
  • Citadel Advisors first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Citadel Advisors's Ovid Therapeutics position peaked at $1.3M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.